Shire's Wellhoefer On Genetic Disease R&D And Expanding Access To Medicines

Scrip spoke with Shire's Head of Genetic Diseases, Medical Affairs, Hartmann Wellhoefer about upcoming milestones in the company's R&D pipeline and improving access to medicines for rare diseases after the Baxalta merger.

DNA detail background with selective focus

Shire PLC Vice President Hartmann Wellhoefer, Head of Genetic Diseases, Medical Affairs, recently spoke with Scrip about the company's research and development pipeline in lysosomal disorders and hereditary angioedema (HAE), noting that more patients with those conditions will have access to Shire's medicines after its purchase of Baxalta Inc.

"The biggest advantage in genetic diseases from Baxalta was expanding our presence into more countries," Wellhoefer said in a Feb....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip